© Datamonitor the home of Business Intelligence intuitive deliveryexpert analysisquality data © Datamonitor

PharmaVitae: Otsuka CSHCXXXX Slidepack XX/10 quality dataexpert analysisintuitive delivery the home of Business Intelligence

Otsuka prescription pharmaceutical performance, sales ($m) and growth rate (%), 2004–16

Abilify contribution, sales ($m) 2004–16

SWOT analysis of Otsuka Strong relationship with US and European pharma companies Abilify will drive revenue growth in the near-term Strengths Potential pitfalls in managing the impact of Abilify’s patent expiry Failure to capitalize on CNS market presence Weaknesses Growing oncology portfolio Launches in broad range of therapeutic areas. Opportunities Competitor expansion following M&A activity Small-molecule focus leads to high exposure to generic erosion Threats

PharmaceuticalOther businesses Otsuka Pharmaceutical Factory Taiho Pharmaceutical Otsuka Pharmaceutical Other chemicals electronics logistics Consumer food and beverages Nutraceuticals CNS Oncology CV IV Solutions Diagnostics Medical devices API’s cosmetics OTC quasi-drugs Current corporate structure

Key product sales ($m), 2004–16

Otsuka key product growth drivers and resistors ($m), 2004–10

Otsuka key product growth drivers and resistors ($m), 2010–16

Otsuka prescription pharmaceutical sales by therapy area ($m), 2004–16

Otsuka prescription pharmaceutical sales by geographic region ($m), 2004–16

Otsuka launch, core and expiry configuration, sales ($m), 2010–16

Otsuka prescription pharmaceutical sales by molecule type ($m), 2004–16

Otsuka prescription pharmaceutical sales by source of product ($m), 2004–16

Abilify sales ($m), 2004–16

Pleetal sales ($m), 2004–16

TS-1 sales ($m), 2004–16

© Datamonitor the home of Business Intelligence intuitive deliveryexpert analysisquality data © Datamonitor